FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311755508> ?p ?o ?g. }

• W4311755508 abstract "Abstract Background In the last few years the role of gut microbiome in human health has been reported. Growing evidence indicate that it is linked to intestinatal diseases, such as the irritable bowel syndrome (IBS), and atherosclerotic disorders. The effect on lipid metabolism seems to be one of the potential mechanisms by which gut microbiome might favour the atherosclerotic process. IBS is a functional bowel disorder defined by the presence of recurrent episodes of abdominal pain associated with altered bowel habits. The severity of psychological and gastrointestinal symptoms in IBS has been linked with a distinct intestinal microbiota signature. In this retrospective study the effect of a novel nutraceutical compound, namely Triobiotix, on gastrointestinal symptoms in IBS patients has been evaluated. Effects on lipid profile have bee also recorded. Methods Triobiotix is a nutraceutical consisting of: Maltodextrin; mineralized extract of Lithothamnion (Lithothamnion calcareum (Pallas) Areschoug, thallus dry extract); Bioecolians® gluco-oligosaccharides; Ferment mix (corn starch, Bifidobacterium animalis ssp. Lactis BLC1 (DSM 17741), Lactobacillus acidophilus LA3 (DSM 17742), Lactobacillus rhamnosus IMC 501 (DSM 16104), Lactobacillus paracasei Streptococc5 501 IMC102 SP4 (DSM 19385); short-chain fructo-oligosaccharides powder. The database of 40 Italian General Practitioners (GPs) were analyzed. At total of 587 patients with IBS and on Triobiotix were identified. Of these in only 535, a complete first and second control data was available. The primary endpoint of these analysis was to assess whether Triobiotix resulted in a reduction in pain and meteorism, thus resulting in a lesser intensity of the main gastrointestinal symptoms. Secondary endpoints were to look for significative changes in lab values of total cholesterol, triglycerides levels and glycaemia. Results Treatment with Triobiotix for four weeks resulted in a reduction in the frequency and intensity of bloating, abdominal pain, and tenesmus. Unexpectedly, at the T1 control, mean cholesterol values were significatively reduced compared to the T0 evaluation. Triglycerides levels were also significantly decreased (186.37±66.4 vs. 176.13±67.9; p &lt; 0.05). Conclusions Our analysis showed an unexpected effect of this combination of micronutrients on lipid profile beyond IBS symptoms. However, further studies are needed to confirm this evidence and to evaluate the particular compound responsible of this effect. A goal of LDL-C less of 115mg/dL is desirable for patients at low to moderate CVR, a significative portion of population is far from this target. The discovery of novel micronutrients combinations with cholesterol lowering effects could be of great importance for the management of patients with low-moderate dyslipidaemia." @default.
• W4311755508 created "2022-12-28" @default.
• W4311755508 creator A5003608436 @default.
• W4311755508 creator A5003825338 @default.
• W4311755508 creator A5027021606 @default.
• W4311755508 creator A5035857177 @default.
• W4311755508 creator A5042393242 @default.
• W4311755508 creator A5070014524 @default.
• W4311755508 creator A5070511718 @default.
• W4311755508 creator A5089522910 @default.
• W4311755508 date "2022-12-14" @default.
• W4311755508 modified "2023-09-26" @default.
• W4311755508 title "682 UNEXPECTED TRIGLYCERIDES-LOWERING EFFECT OF A NOVEL NUTRACEUTICAL COMPOUND FOR IBS" @default.
• W4311755508 doi "https://doi.org/10.1093/eurheartjsupp/suac121.152" @default.
• W4311755508 hasPublicationYear "2022" @default.
• W4311755508 type Work @default.
• W4311755508 citedByCount "0" @default.
• W4311755508 crossrefType "journal-article" @default.
• W4311755508 hasAuthorship W4311755508A5003608436 @default.
• W4311755508 hasAuthorship W4311755508A5003825338 @default.
• W4311755508 hasAuthorship W4311755508A5027021606 @default.
• W4311755508 hasAuthorship W4311755508A5035857177 @default.
• W4311755508 hasAuthorship W4311755508A5042393242 @default.
• W4311755508 hasAuthorship W4311755508A5070014524 @default.
• W4311755508 hasAuthorship W4311755508A5070511718 @default.
• W4311755508 hasAuthorship W4311755508A5089522910 @default.
• W4311755508 hasBestOaLocation W43117555081 @default.
• W4311755508 hasConcept C100544194 @default.
• W4311755508 hasConcept C126322002 @default.
• W4311755508 hasConcept C142724271 @default.
• W4311755508 hasConcept C17857428 @default.
• W4311755508 hasConcept C203014093 @default.
• W4311755508 hasConcept C2775913212 @default.
• W4311755508 hasConcept C2776651480 @default.
• W4311755508 hasConcept C2776956441 @default.
• W4311755508 hasConcept C2778271842 @default.
• W4311755508 hasConcept C2780206646 @default.
• W4311755508 hasConcept C2780955771 @default.
• W4311755508 hasConcept C31903555 @default.
• W4311755508 hasConcept C539455810 @default.
• W4311755508 hasConcept C71924100 @default.
• W4311755508 hasConcept C86803240 @default.
• W4311755508 hasConcept C90924648 @default.
• W4311755508 hasConceptScore W4311755508C100544194 @default.
• W4311755508 hasConceptScore W4311755508C126322002 @default.
• W4311755508 hasConceptScore W4311755508C142724271 @default.
• W4311755508 hasConceptScore W4311755508C17857428 @default.
• W4311755508 hasConceptScore W4311755508C203014093 @default.
• W4311755508 hasConceptScore W4311755508C2775913212 @default.
• W4311755508 hasConceptScore W4311755508C2776651480 @default.
• W4311755508 hasConceptScore W4311755508C2776956441 @default.
• W4311755508 hasConceptScore W4311755508C2778271842 @default.
• W4311755508 hasConceptScore W4311755508C2780206646 @default.
• W4311755508 hasConceptScore W4311755508C2780955771 @default.
• W4311755508 hasConceptScore W4311755508C31903555 @default.
• W4311755508 hasConceptScore W4311755508C539455810 @default.
• W4311755508 hasConceptScore W4311755508C71924100 @default.
• W4311755508 hasConceptScore W4311755508C86803240 @default.
• W4311755508 hasConceptScore W4311755508C90924648 @default.
• W4311755508 hasIssue "Supplement_K" @default.
• W4311755508 hasLocation W43117555081 @default.
• W4311755508 hasOpenAccess W4311755508 @default.
• W4311755508 hasPrimaryLocation W43117555081 @default.
• W4311755508 hasRelatedWork W1922457294 @default.
• W4311755508 hasRelatedWork W2018925772 @default.
• W4311755508 hasRelatedWork W2032837696 @default.
• W4311755508 hasRelatedWork W2098294301 @default.
• W4311755508 hasRelatedWork W2183768895 @default.
• W4311755508 hasRelatedWork W2977661422 @default.
• W4311755508 hasRelatedWork W2978863793 @default.
• W4311755508 hasRelatedWork W3019005669 @default.
• W4311755508 hasRelatedWork W3148666790 @default.
• W4311755508 hasRelatedWork W4283272898 @default.
• W4311755508 hasVolume "24" @default.
• W4311755508 isParatext "false" @default.
• W4311755508 isRetracted "false" @default.
• W4311755508 workType "article" @default.